Voriconazole prophylaxis in lung transplant recipients

Area of Science:

• Medical Mycology
• Transplant Infectious Diseases
• Pharmacology

Background:

• Lung transplant recipients face high risks of invasive aspergillosis (IA).
• Fungal infection management strategies vary, impacting patient outcomes.
• Aspergillus colonization is a key risk factor for IA post-transplant.

Purpose of the Study:

• To compare the efficacy of universal voriconazole prophylaxis versus targeted prophylaxis for IA prevention in lung transplant recipients.
• To assess the safety profile, including adverse events and medication discontinuation rates, of different antifungal prophylaxis strategies.

Main Methods:

• Retrospective, sequential study design at a single center.
• Comparison of two groups: universal voriconazole prophylaxis (n=65) and targeted prophylaxis (itraconazole +/- inhaled amphotericin) for high-risk patients (n=30).
• Evaluation of IA rates at 1 year and analysis of adverse events, including liver enzyme elevations and drug discontinuation.

Main Results:

• IA rate at 1 year was significantly lower with voriconazole prophylaxis (1.5%) compared to targeted prophylaxis (23%; p=0.001).
• A notable proportion of IA cases in the targeted group occurred in patients colonized with Aspergillus niger.
• Increased liver enzymes were observed in 37-60% of patients on voriconazole versus 15-41% in the targeted group. Discontinuation due to side effects occurred in 14% (voriconazole) vs. 8% (targeted).

Conclusions:

• Universal voriconazole prophylaxis is effective in preventing invasive aspergillosis in lung transplant recipients.
• Voriconazole prophylaxis requires careful monitoring for hepatotoxicity and potential side effects necessitating drug discontinuation.
• Monitoring of liver enzymes and calcineurin inhibitor levels is crucial to mitigate risks associated with voriconazole use.